Diana Ernst, RPh, Author at Psychiatry Advisor

Diana Ernst, RPh

All articles by Diana Ernst, RPh

Adhansia XR Soon to Be Available for ADHD

Adhansia XR (methylphenidate HCl extended-release capsules) is expected to be available as of July 15, 2019 for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years of age and older, according to Adlon Therapeutics.

Novel Treatment for Schizophrenia Gets FDA’s Breakthrough Therapy Designation

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia. SEP-363856 is believed to work by activating trace amine-associated receptor 1 (TAAR1) in addition to 5-HT1A receptors; unlike other antipsychotics, this novel agent does not bind to D2 or 5-HT2A receptors. The Breakthrough Therapy designation was…

Next post in Schizophrenia and Psychoses